There are several limitations to the CMS negotiation approach illustrated in this example, starting with the dubious implicit assumption that the prices for therapeutic alternatives will be fair. Once ...
Certain features of the drugs selected for first-year negotiation could limit CMS’s pricing flexibility. To enhance program predictability and provide clear signals to the pharmaceutical industry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results